Unlike most comparisons on this blog, this one is between two FDA-approved medications with large clinical trials behind them, so we can speak more plainly. Here's how semaglutide and tirzepatide differ.
What each one is
Semaglutide is a GLP-1 receptor agonist, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Tirzepatide acts on two receptors, GIP and GLP-1, and is sold as Mounjaro for diabetes and Zepbound for weight management. Both are backed by large randomized trials.
The practical difference
The headline distinction is mechanism: semaglutide targets one pathway, tirzepatide two. In trials, the dual-pathway approach has been associated with notable results, but the right choice for any individual depends on their health profile, history, and a clinician's judgment, not on which one trends online.
What we won't do
We don't publish dosing or titration schedules, even for approved drugs, those belong with a prescriber. And steer clear of "research" or "generic" versions sold outside legitimate channels; there's no FDA-approved generic of either.
Bottom line
Two approved GLP-1-class options, different mechanisms, both effective in trials, with the choice individualized by a provider. See our GLP-1 overview and the semaglutide and tirzepatide guides.